• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • May 20, 2020
    Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session
    -Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented-
  • May 7, 2020
    Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
  • May 7, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 5, 2020
    Insmed Announces Pricing of Public Offering of Common Stock
  • May 4, 2020
    Insmed Announces Proposed Public Offering of Common Stock
  • Apr 30, 2020
    Insmed Reports First Quarter 2020 Financial Results and Provides Business Update
    --Company Supports Investigator-Initiated Study of Brensocatib (Formerly INS1007) in Severe COVID-19 and Continues to Advance Development in Bronchiectasis--
  • Apr 23, 2020
    Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial
    --Insmed to support STOP-COVID19 Study, Expected to Begin in the UK in May 2020--
  • Apr 20, 2020
    Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020
  • Apr 3, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Apr 2, 2020
    Insmed Appoints Carol A. Schafer to its Board of Directors
  • Mar 16, 2020
    Insmed Provides Business Update
    -- Company Submits New Drug Application in Japan for ARIKAYCE® (amikacin liposome inhalation suspension) for the Treatment of Patients with NTM Lung Disease Caused by MAC --
  • Mar 5, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 4, 2020
    Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal Open Forum Infectious Disease
    -- Management of common adverse events through physician-guided measures resulted in symptomatic improvement --
  • Feb 26, 2020
    Insmed to Present at the Cowen and Company 40th Annual Health Care Conference
  • Feb 25, 2020
    Insmed Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $45.7 Million for the Fourth Quarter 2019 and $136.5 Million for the Full Year 2019--
  • Feb 19, 2020
    Insmed to Present at the 9th Annual SVB Leerink Global Healthcare Conference
  • Feb 10, 2020
    Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020
  • Feb 5, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Feb 3, 2020
    Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study of INS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis
    -- Study Achieves Primary Endpoint with Statistically Significant Improvement in Time to First Exacerbation for Both Dosage Strengths of INS1007 Versus Placebo --
  • Jan 30, 2020
    Insmed Appoints Sara Bonstein as Chief Financial Officer
  • Jan 9, 2020
    Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference
    • Photos 1
  • Jan 3, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Dec 3, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 26, 2019
    Insmed to Present at Two December Conferences
  • Nov 14, 2019
    Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer
    -Drayton Wise named Senior Vice President, Head of U.S.
  • Nov 5, 2019
    Insmed to Present at Two November Conferences
  • Nov 4, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Oct 30, 2019
    Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019--
  • Oct 23, 2019
    Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019
  • Oct 7, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 5, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 3, 2019
    Insmed to Present at Two September Conferences
  • Aug 2, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 1, 2019
    Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $29.0 Million for the Second Quarter of 2019--
  • Jul 25, 2019
    Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019
  • Jul 2, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 26, 2019
    Insmed Announces Closing of Public Offering of Common Stock
  • Jun 6, 2019
    Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  • Jun 4, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 24, 2019
    Insmed Announces Closing of Public Offering of Common Stock
  • May 21, 2019
    Insmed Announces Pricing of Public Offering of Common Stock
  • May 20, 2019
    Insmed Announces Proposed Public Offering of Common Stock
  • May 20, 2019
    New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
    --ARIKAYCE Plus Guideline-Based Therapy (GBT) Associated with Significantly Higher Rates of Sustained Culture Conversion on Therapy and Durable Culture Conversion Three Months Post-Treatment Compared with GBT Alone--
  • May 7, 2019
    Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
    -- ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Net Product Sales $21.0 Million for the First Quarter of 2019 --
  • Apr 30, 2019
    Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019
  • Apr 9, 2019
    Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
    --Patent is 10th Issued in the U.S. for ARIKAYCE and Second Extending Patent Protection into 2035--
  • Apr 8, 2019
    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
    --ARIKAYCE Preliminary U.S. Net Product Sales Approximately $21.0 Million for the First Quarter of 2019--
  • Apr 2, 2019
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Apr 1, 2019
    Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
    --Sustainability and Durability Data from Phase 3 CONVERT Study of ARIKAYCE to be Presented in Late-Breaking Oral Session--
  • Apr 1, 2019
    Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy